Keyphrases
Israeli
100%
Thrombocytosis
100%
Group Studies
100%
Endometrial Cancer
100%
Prognostic Significance
100%
Gynecologic Oncology Group
100%
Platelet Count
50%
Overall Survival
50%
Disease-specific Survival
50%
Endometrioid
50%
Lymphovascular Invasion
33%
Stage I Disease
33%
Histology
16%
High Risk
16%
Multivariate Analysis
16%
Cancer Patients
16%
Consecutive Patients
16%
Disease Stage
16%
Clinical Features
16%
Low Risk
16%
Cox Proportional Hazards Model
16%
Multivariable
16%
Student's T-test
16%
Patient Outcomes
16%
Poor Outcome
16%
Patients Included
16%
Lymph Node Metastasis
16%
Clear Cell Carcinoma
16%
Obstetrics
16%
Advanced Stage
16%
Kaplan-Meier Method
16%
Patient with Tumor
16%
Pelvic Lymph Nodes
16%
Salpingo-oophorectomy
16%
Lymph Node Sampling
16%
Pathological Features
16%
Fisher's Exact Test
16%
Surgeons
16%
5-year Survival
16%
Log-rank Test
16%
Cancer Prognosis
16%
Uterine Serous Carcinoma
16%
Independent Prognostic Factor
16%
Thrombocyte Count
16%
Total Abdominal Hysterectomy
16%
Carcinosarcoma
16%
Survival Statistics
16%
International Federations
16%
Lower Uterine Segment
16%
Multicenter Retrospective Cohort Study
16%
Myometrial Invasion
16%
Deep Myometrial Invasion
16%
Laparoscopic Hysterectomy
16%
Villoglandular
16%
High-grade Malignancy
16%
High Risk Histology
16%
Pelvic Washings
16%
Medicine and Dentistry
Thrombocytosis
100%
Gynecological Oncology
100%
Uterine Cancer
100%
Platelet
66%
Overall Survival
50%
Disease Specific Survival
50%
Diseases
50%
Lymph Duct
33%
Pelvis
33%
Retrospective Cohort Study
16%
Multivariate Analysis
16%
Neoplasm
16%
Proportional Hazards Model
16%
Lymph Node
16%
Cancer
16%
Surgeon
16%
Lymph Node Metastasis
16%
Clear Cell Carcinoma
16%
Hysterectomy
16%
Obstetrics
16%
Student T Test
16%
Kaplan Meier Method
16%
Salpingooophorectomy
16%
Disease Free Survival
16%
Prognostic Factor
16%
Fisher Exact Test
16%
Cytotechnology
16%
Cancer Prognosis
16%
Endometrium Carcinoma
16%
Gynecology
16%
Log Rank Test
16%
Carcinosarcoma
16%